[New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma]

Natacha Naoun; Yann-Alexandre Vano

doi:10.1016/j.bulcan.2021.05.005

[New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma]

Bull Cancer. 2021 Nov;108(11):991-993. doi: 10.1016/j.bulcan.2021.05.005. Epub 2021 Sep 17.

[Article in French]

Authors

Natacha Naoun¹, Yann-Alexandre Vano²

Affiliations

¹ Institut de cancérologie de Lorraine, département d'oncologie médicale, 54500 Vandœuvre-les-Nancy, France. Electronic address: natacha.naoun@gmail.com.
² Assistance publique-Hôpitaux de Paris (AP-HP) Paris-Centre, Hôpital européen Georges-Pompidou, service d'oncologie médicale, 75015 Paris, France.

PMID: 34538614
DOI: 10.1016/j.bulcan.2021.05.005

No abstract available

Keywords: Advanced renal clear cell carcinoma; Anti-PD1; Carcinome rénal à cellules claires avancé; Combinaison thérapeutique; Inhibiteurs de tyrosine kinases (ITK) anti-VEGFR; Therapeutic combination; Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs).

Publication types

News

MeSH terms

Anilides / therapeutic use*
Antineoplastic Agents / therapeutic use*
Carcinoma, Renal Cell / drug therapy*
Carcinoma, Renal Cell / pathology
Drug Approval*
Humans
Kidney Neoplasms / drug therapy*
Kidney Neoplasms / pathology
Nivolumab / therapeutic use*
Protein Kinase Inhibitors / therapeutic use
Pyridines / therapeutic use*
Randomized Controlled Trials as Topic
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

Substances

Anilides
Antineoplastic Agents
Protein Kinase Inhibitors
Pyridines
cabozantinib
Nivolumab
Receptors, Vascular Endothelial Growth Factor